A high quality GLP1 pill: once-daily Orforglipron
We take a look at the most recent set of results from Orforglipron, the oral GLP1 from Eli Lilly
Latest
CagriSema underperforms in trial
We take a look at the recent results for CagriSema, and see how it tracks against other GLP1s
Kidney injuries on Ozempic
Recent reports of kidney injuries have caused a change in requirements for GLP1 labeling. We dive into the actual risk and what you can do about it.
Mounjaro vs Trulicity in a clinical trial
Trulicity and Mounjaro go head to head, in a clinical trial that finally puts to bed the question of which is better.
Medicare/Medicaid might pay for GLP1s again
GLP1s might be covered under Medicare/medicaid again. The Trump administration introduces a new experiment under the CMMI.
Boosting GLP1s with Phentermine
Reports of combining GLP1s with Phentermine suggest superior results. What is Phentermine and how can it be used with GLP1s?
Another GLP1 Generic launch: India's Dr Reddy's
Yet another manufacturer signs up to produce generic Semaglutide for much of the world (ex. EU and USA) - what does Dr. Reddy's have planned?
Hims will sell generic Semaglutide in 2026
Hims is going to start selling generic Semaglutide in 2026, long before US patents expire. How?
Novo Nordisk is introducing a higher dose of Wegovy
Novo Nordisk is looking to introduce a new higher dosage of Semaglutide (Wegovy) -- we take a look at the studies they *didn't* submit.
Novo's expanding collaboration with Weight Watchers
Novo Nordisk expanded their collaboration with Weight Watchers, offering an introductory price of $299
Less for Less: CVS drops Zepbound for Wegovy
CVS Health drops coverage of the more effective Tirzepatide (Zepbound) for Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda).
If GLP1 is so great, why don't people stick with it?
Why are so few people able to stay on GLP1s for 3 years? We dig into the analysis & report by Prime Therapeutics.
category:news
A glowing endorsement of GLP1s by cardiologists
Reflection on the ACC's endorsement of GLP1s as a first-line approach to weight management and improving cardiovascular outcomes.
category:risks
A new risk? Macular Degeneration
We explore the new GLP1 risk factor for macular degeneration (nAMD) that has been reported in a study published to JAMA.
drug:orforglipron
Updates from MariTide & Orforglipron research
MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.
chemical:semaglutide
After two months, Novo Nordisk and HIMS part ways
Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.
category:news
Preserving muscle: GLP1s with Bimagrumab
We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.
company:novo-nordisk
Novo Nordisk patent protections lapse in Canada
Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.
category:news
A challenge to Eli Lilly's Tirzepatide patent
Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.
drug:eloralinitide
Amylin, with and without GLP1: Eloralinitide
We dig into early results around Eloralinitide, an amylin-based weight loss formulation being developed by Eli Lilly.
category:side-effects
Ozempic is not likely to directly enlarge the male appendage.
A critical look at the popular "ozempic penis" claims and look at the sources, along with possible reasons and related research.
company:eli-lilly
Eli Lilly's big Summer 2025 update
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
research
Semaglutide vs Tirzepatide (Clinical trial)
Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.
company:roche
Roche and Carmot's GLP1 pipeline
We take a look at Roche (via Carmot)'s GLP1 pipeline development, and figure out how CT-388, CT-996, and CT-868 are trending.